Dynorphin B (1-13) is primarily studied for its role in the central nervous system, where it acts as an endogenous opioid peptide. It is involved in modulating pain perception and stress responses. Research focuses on its potential therapeutic applications in managing chronic pain, as it interacts with kappa opioid receptors to produce analgesic effects. Additionally, it is being investigated for its role in neurological disorders, such as depression and addiction, due to its influence on mood and reward pathways. In experimental settings, Dynorphin B (1-13) is used to study opioid receptor signaling and its implications in neurophysiology and pharmacology.